Hikma Invests $1 Billion to Expand its Manufacturing and R&D Operations
Introduction:
Hikma Pharmaceuticals USA has unveiled a strategic plan to invest $1 billion by the year 2030 to expand its manufacturing and research capabilities within the United States. This major investment is designed to bolster the company’s role in delivering a wide array of essential medications to the U.S. healthcare system.
Features:
As part of its initiative, America Leans on Hikma: Quality Medicines Manufactured in the USA, the company aims to boost domestic production of reliable, cost-effective generic drugs.
This initiative will leverage Hikma’s current infrastructure to further support the development and supply of critical treatments for patients nationwide.
The expansion will center on existing facilities located in Columbus and Cleveland, Ohio, as well as Cherry Hill and Dayton, New Jersey.
These efforts will enhance the company’s ability to serve its portfolio of more than 800 products, with particular emphasis on strengthening its capabilities in sterile injectable medicines, a segment in which Hikma ranks among the top three U.S. suppliers, offering over 180 products.
In addition to improving production capacity, this investment is expected to generate new employment opportunities and enhance the resilience of the domestic pharmaceutical supply chain.
The expansion is expected to be completed by the year 2030.
Specifications:
| Name | Hikma |
| Budget | $1 Billion |
| Type | Expansion |
| Year | 2030 |
